Dual Honors Achieved: Huihe Medical Named to 'Future Healthcare 100' and K-Clip® Wins Innovation Award
H&H Healthcare
R&D and Producer of Interventional Medical Devices for Heart Disease
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
May 9-10, 2025, co-hosted by VBEF and Arterial Network2025 Future Healthcare and Pharmaceutical 100强 Expo (2025VBEF)Held at the Suzhou International Expo Center.
"Future Healthcare 100 Strong" is one of the authoritative evaluation systems in China's healthcare innovation field. HuiHe Healthcare successfully made it to the list with its outstanding innovation capabilities and intelligent manufacturing level."2025 Future Healthcare 100 Strong · Top 100 List of China's Innovative Medical Devices and Intelligent Manufacturing"! And with its independently developed K-Clip® Transcatheter Tricuspid Annuloplasty System, it won "Cardiovascular Interventional Value Product/Solution Award”。
Hardcore Technology Leads the Industry, K-Clip®Fill the Gap in China
As the first approved transcatheter tricuspid valve intervention device in China, K-Clip®Approved for marketing by the National Medical Products Administration (NMPA) in March 2025. This marks a significant breakthrough in the treatment of tricuspid regurgitation in China and ushers in a new era globally for TTVA (Transcatheter Tricuspid Valve Annuloplasty) in treating tricuspid regurgitation.
Currently, K-Clip®Officially Launched Post-Market Commercial Implantation, Academician Ge Junbo's Team from Fudan University Affiliated Zhongshan Hospital, Academician Wang Jian'an's Team from The Second Affiliated Hospital of Zhejiang University School of Medicine, and Professor Song Guangyuan from Beijing Anzhen Hospital, Capital Medical University, along with Professor Lin Yixian from four top cardiac centers, Successfully Applied K-Clip on the Same Day in Three Locations®Completed the first implantation after the product's market launch.
At the same time, K-Clip®Dozens of clinical research surgeries have been successfully conducted in the United States, Spain, the United Kingdom, Canada, Hong Kong, China, and other countries and regions, receiving high praise from overseas experts.
In the future, HuiHe Healthcare will take independent research and innovation as the core driving force, deeply integrate industry-academia-research resources, promote the globalization of high-end medical devices, and provide better life protection solutions for patients worldwide.